Readers are referred to the cautionary note regarding Forward-looking Information at the end of this release. WINNIPEG, July 10, 2012 /CNW/ - Cangene Corporation (Cangene) today announces that ...
Researchers will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. IGIV is ...
Washington, DC and Glendale, CA - In the wake of postmarketing reports describing serious thrombotic events possibly associated with administration of immune globulin intravenous (IGIV), the American ...
Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG ...
TORONTO (April 13, 2010) -- An investigational intervention using naturally ocurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's ...
HealthFirst reporter Leslie Toldo tells us about the research that could affect millions of families in the future. Right now, the only drugs available to treat Alzheimer's are designed to relieve the ...
Baxter and the Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients with Alzheimer's Disease Preliminary Phase II Results Encouraging and Support ...
An investigational intervention using naturally occurring antibodies in human blood has preserved the thinking abilities of a group of mild- to moderate-stage Alzheimer's patients over 18 months and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results